Interobserver variability in tumor contouring affects the use of radiomics to predict mutational status

被引:35
作者
Huang, Qiao [1 ]
Lu, Lin [1 ]
Dercle, Laurent [1 ]
Lichtenstein, Philip [1 ]
Li, Yajun [1 ]
Yin, Qian [1 ]
Zong, Min [1 ]
Schwartz, Lawrence [1 ]
Zhao, Binsheng [1 ]
机构
[1] Columbia Univ, Med Ctr, Dept Radiol, New York, NY 10027 USA
关键词
radiomics; epidermal growth factor receptor; nonsmall cell lung cancer; contouring; variability;
D O I
10.1117/1.JMI.5.1.011005
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Radiomic features characterize tumor imaging phenotype. Nonsmall cell lung cancer (NSCLC) tumors are known for their complexity in shape and wide range in density. We explored the effects of variable tumor contouring on the prediction of epidermal growth factor receptor (EGFR) mutation status by radiomics in NSCLC patients treated with a targeted therapy (Gefitinib). Forty-six early stage NSCLC patients (EGFR mutant: wildtype = 20: 26) were included. Three experienced radiologists independently delineated the tumors using a semiautomated segmentation software on a noncontrast-enhanced baseline and three-week post-therapy CT scan images that were reconstructed using 1.25-mm slice thickness and lung kernel. Eighty-nine radiomic features were computed on both scans and their changes (radiomic delta-features) were calculated. The highest area under the curves (AUCs) were 0.87, 0.85, and 0.80 for the three radiologists and the number of significant features (AUC > 0.8) was 3, 5, and 0, respectively. The AUCs of a single feature significantly varied among radiologists (e.g., 0.88, 0.75, and 0.73 for run-length primitive length uniformity). We conclude that a three-week change in tumor imaging phenotype allows identifying the EGFR mutational status of NSCLC. However, interobserver variability in tumor contouring translates into a significant variability in radiomic metrics accuracy. (c) 2017 Society of Photo-Optical Instrumentation Engineers (SPIE)
引用
收藏
页数:9
相关论文
共 28 条
[11]   Outcomes of patients with advanced non-small cell tung cancer treated with gefitinib (ZD1839, 'Iressa') on an expanded access study [J].
Jänne, PA ;
Gurubhagavatula, S ;
Yeap, BY ;
Lucca, J ;
Ostler, P ;
Skarin, AT ;
Fidias, P ;
Lynch, TJ ;
Johnson, BE .
LUNG CANCER, 2004, 44 (02) :221-230
[12]   Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial [J].
Kris, MG ;
Natale, RB ;
Herbst, RS ;
Lynch, TJ ;
Prager, D ;
Belani, CP ;
Schiller, JH ;
Kelly, K ;
Spiridonidis, H ;
Sandler, A ;
Albain, KS ;
Cella, D ;
Wolf, MK ;
Averbuch, SD ;
Ochs, JJ ;
Kay, AC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (16) :2149-2158
[13]   Assessing Agreement between Radiomic Features Computed for Multiple CT Imaging Settings [J].
Lu, Lin ;
Ehmke, Ross C. ;
Schwartz, Lawrence H. ;
Zhao, Binsheng .
PLOS ONE, 2016, 11 (12)
[14]   Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].
Lynch, TJ ;
Bell, DW ;
Sordella, R ;
Gurubhagavatula, S ;
Okimoto, RA ;
Brannigan, BW ;
Harris, PL ;
Haserlat, SM ;
Supko, JG ;
Haluska, FG ;
Louis, DN ;
Christiani, DC ;
Settleman, J ;
Haber, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139
[15]   Annual number of lung cancer deaths potentially avertable by screening in the United States [J].
Ma, Jiemin ;
Ward, Elizabeth M. ;
Smith, Robert ;
Jemal, Ahmedin .
CANCER, 2013, 119 (07) :1381-1385
[16]   Guidelines for management of small pulmonary nodules detected on CT scans: A statement from the Fleischner Society [J].
MacMahon, H ;
Austin, JHM ;
Gamsu, G ;
Herold, CJ ;
Jett, JR ;
Naidich, DP ;
Patz, EF ;
Swensen, SJ .
RADIOLOGY, 2005, 237 (02) :395-400
[17]   Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer [J].
Miller, VA ;
Kris, WG ;
Shah, N ;
Patel, J ;
Azzoli, C ;
Gomez, J ;
Krug, LM ;
Pao, W ;
Rizvi, N ;
Pizzo, B ;
Tyson, L ;
Venkatraman, E ;
Ben-Porar, L ;
Memoli, N ;
Zakowski, M ;
Rusch, V ;
Heelan, RT .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1103-1109
[18]   Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. [J].
Mok, Tony S. ;
Wu, Yi-Long ;
Thongprasert, Sumitra ;
Yang, Chih-Hsin ;
Chu, Da-Tong ;
Saijo, Nagahiro ;
Sunpaweravong, Patrapim ;
Han, Baohui ;
Margono, Benjamin ;
Ichinose, Yukito ;
Nishiwaki, Yutaka ;
Ohe, Yuichiro ;
Yang, Jin-Ji ;
Chewaskulyong, Busyamas ;
Jiang, Haiyi ;
Duffield, Emma L. ;
Watkins, Claire L. ;
Armour, Alison A. ;
Fukuoka, Masahiro .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (10) :947-957
[19]   EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy [J].
Paez, JG ;
Jänne, PA ;
Lee, JC ;
Tracy, S ;
Greulich, H ;
Gabriel, S ;
Herman, P ;
Kaye, FJ ;
Lindeman, N ;
Boggon, TJ ;
Naoki, K ;
Sasaki, H ;
Fujii, Y ;
Eck, MJ ;
Sellers, WR ;
Johnson, BE ;
Meyerson, M .
SCIENCE, 2004, 304 (5676) :1497-1500
[20]   Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer. [J].
Rosell, Rafael ;
Moran, Teresa ;
Queralt, Cristina ;
Porta, Rut ;
Cardenal, Felipe ;
Camps, Carlos ;
Majem, Margarita ;
Lopez-Vivanco, Guillermo ;
Isla, Dolores ;
Provencio, Mariano ;
Insa, Amelia ;
Massuti, Bartomeu ;
Luis Gonzalez-Larriba, Jose ;
Paz-Ares, Luis ;
Bover, Isabel ;
Garcia-Campelo, Rosario ;
Angel Moreno, Miguel ;
Catot, Silvia ;
Rolfo, Christian ;
Reguart, Noemi ;
Palmero, Ramon ;
Miguel Sanchez, Jose ;
Bastus, Roman ;
Mayo, Clara ;
Bertran-Alamillo, Jordi ;
Angel Molina, Miguel ;
Javier Sanchez, Jose ;
Taron, Miquel .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (10) :958-U38